Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna and BioNTech Stocks Dropped Today

By Joe Tenebruso - Jun 14, 2021 at 5:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine makers are likely to face intensifying competition.

What happened

Shares of Moderna (MRNA -5.06%) and BioNTech (BNTX -2.91%) fell 5.2% and 7.5%, respectively, on Monday after rival COVID-19 vaccine maker Novavax (NVAX -5.56%) announced favorable clinical trial results. 

So what 

Novavax's vaccine candidate, NVX-CoV2373, demonstrated overall efficacy of 90.4% in a phase 3 study with nearly 30,000 participants. The drug was also shown to provide 100% protection against moderate and severe forms of COVID-19. Additionally, it was generally well-tolerated among the trial's participants.

"These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus," Novavax president of research and development Gregory Glenn said in a press release.

A person in medical gear is holding a drug vial labeled coronavirus.

Image source: Getty Images.

These results are close to those that were achieved by the Moderna and Pfizer/BioNTech vaccines. Novavax could thus emerge as a formidable new competitor to the leading COVID-19 drugmakers. "Our vaccine will be a critical part of the solution to COVID-19," Glenn said.

Now what

Novavax intends to file for regulatory authorizations in the third quarter. The biotech said it could manufacture 150 million doses per month by the end of this year.

While some countries, such as the U.S., have already acquired the vaccine doses they need, many other countries have yet to do so. Novavax could thus see strong demand for its vaccine in international markets -- and potentially wrestle away some market share from Moderna and BioNTech.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$37.18 (-5.56%) $-2.19
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00
BioNTech SE Stock Quote
BioNTech SE
BNTX
$147.61 (-2.91%) $-4.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.